Bellicum Pharmaceuticals

Home » Bellicum Pharmaceuticals

Secondary

Bellicum Pharmaceuticals

We are a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders.

Symbol

BLCM

Final Price
$8.97

Shares
8,000,000

Anticipated Date
TBD

Underwriters
Citigroup, Jefferies, Guggenheim, Ladenburg Thalman, Raymond James

To view the prospectus for Bellicum Pharmaceuticals, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253